Japan Generics Market Analysis

Japan Generics Market Analysis


February 1, 2012
55 Pages - SKU: CICQ6800354
License type:
Online Download      US $1,000.00
Hard Copy Mail Delivery      US $1,100.00
CD-ROM Mail Delivery      US $1,100.00
Global Site License      US $1,500.00
Countries covered: Japan

Japan is the world’s second largest pharmaceutical markets in the world, but due to public perception, the share of generic drugs has remained low in it. However, worried over rising healthcare expenses and high mortality rates, the government has now been playing a vital role in promoting generics. The patent expiry of branded drugs and active ingredients will also act as a strong growth driver for the market in future. According to the findings of our latest report, the generics market in Japan stood at around US$ 9 Billion in 2010. It estimates that the growth in generic drugs will outshine the expansion in overall pharmaceutical market.

According to “Japan Generics Market Analysis”, Japan is expected to be the next generic hub, and cancer related generics exhibit vast potential. The report finds out how vital is the role of National Health Insurance (NHI) pharmacies and Diagnosis Procedure Combination (DPC) hospitals in the industry development. It was observed that the DPC hospitals, in particular, have been growing at a robust rate, promoting generics penetration. We also found that ethical generics hold the majority share in the generic drugs market.

A detailed demographic analysis was carried out in the research that revealed that the population aged 65 years and above accounts for maximum healthcare-related expenditures in Japan, and hence becomes the target population for generics promotion. Further, a meticulous disease and age-wise segmentation has provided the holistic understanding of the healthcare-related demand parameters prevailing in the country.

The government in Japan has taken several initiatives to ensure growth and promotion of generics industry in the country. Recently, special premium-based incentives have been given to pharmacists on generic promotion. In near future, the government plans to bring in more reforms in medical care system. Our research talks about such revisions and reforms briefly to present a balanced outlook of the industry to clients. Analysis of current trends, profiles of key players in the Japanese generic market, and recent developments in the industry have also been included in the comprehensive study.



More Manufacturing, Packaging & Detailing reports by RNCOS

Russian Pharmaceutical Market Outlook to 2017 by RNCOS
Russian Pharmaceutical Market Outlook to 2017 The pharmaceutical industry in Russia finally seems ready for a change. With the government adopting ‘Strategy 2020’ to improve ...
Cancer Generics Market Outlook 2017 by RNCOS
The National Cancer Institute has stated that almost half of the population born today will be diagnosed with cancer at some point during their lifetime. ...
Global API Market Forecast to 2017 by RNCOS
The market for Active Pharmaceutical Ingredients is brimming with activities. While it is consolidating in US and EU resulting in the emergence of few big ...
Brazil Healthcare - New Opportunities for Growth by RNCOS
Brazil is considered as one of the most lucrative healthcare market in Latin America with highest healthcare expenditure. Strong government support and high healthcare services ...
See all reports like this >>

More Japan Manufacturing, Packaging & Detailing reports

Japan Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
Japan Pharmaceuticals and Healthcare Report Q2 2014BMI View: Japan's pharmaceutical expenditure forecast has been upgraded marginally on the back of anincrease in medical fees. We ...
Pharmaceuticals in Japan: ISIC 2423 by Euromonitor International
Pharmaceuticals in Japan: ISIC 2423Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to ...
PharmaPoint: Type 2 Diabetes - Japan Drug Forecast and Market Analysis to 2022 by GlobalData
PharmaPoint: Type 2 Diabetes - Japan Drug Forecast and Market Analysis to 2022SummaryGlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - Japan ...
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Japan by GlobalData
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - JapanSummaryGlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Japan”. ...
See all reports like this >>

More Japan reports

D&B Country Report: Japan by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
See all reports like this >>